A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors

被引：0
|
作者：
Rodon, J.
Infante, J.
Burris, H.
Tabernero, J.
Ranson, M. R.
Rouyrre, N.
Duval, V.
Silva, A.
Hackl, W.
Baselga, J.
机构：
[1] Vail Hebron Univ Hosp, Barcelona, Spain
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[4] Novartis Pharma AG, Basel, Switzerland
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/0008-5472.SABCS10-P6-15-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-15-07
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia
    Lan Deng
    Ling Jiang
    Xiang-hua Lin
    Kuo-Fu Tseng
    Yuan Liu
    Xing Zhang
    Rui-hong Dong
    Zhi-gang Lu
    Xiu-ju Wang
    Acta Pharmacologica Sinica, 2017, 38 : 382 - 391
  • [32] The PI3K/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia
    Deng, Lan
    Jiang, Ling
    Lin, Xiang-Hua
    Tseng, Kuo-Fu
    Liu, Yuan
    Zhang, Xing
    Dong, Rui-Hong
    Lu, Zhi-Gang
    Wang, Xiu-Ju
    ACTA PHARMACOLOGICA SINICA, 2017, 38 (03) : 382 - 391
  • [33] A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors
    Toyoda, Masanori
    Watanabe, Koichiro
    Amagasaki, Taro
    Natsume, Kazuto
    Takeuchi, Hiromi
    Quadt, Cornelia
    Shirao, Kuniaki
    Minami, Hironobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 83 (02) : 289 - 299
  • [34] A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors
    Masanori Toyoda
    Koichiro Watanabe
    Taro Amagasaki
    Kazuto Natsume
    Hiromi Takeuchi
    Cornelia Quadt
    Kuniaki Shirao
    Hironobu Minami
    Cancer Chemotherapy and Pharmacology, 2019, 83 : 289 - 299
  • [35] Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
    Dongshao Chen
    Xiaoting Lin
    Cheng Zhang
    Zhentao Liu
    Zuhua Chen
    Zhongwu Li
    Jingyuan Wang
    Beifang Li
    Yanting Hu
    Bin Dong
    Lin Shen
    Jiafu Ji
    Jing Gao
    Xiaotian Zhang
    Cell Death & Disease, 9
  • [36] Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles
    Wu, Binquan
    Li, Amin
    Zhang, Yinci
    Liu, Xueke
    Zhou, Shuping
    Gan, Huaiyong
    Cai, Shiyu
    Liang, Yong
    Tang, Xiaolong
    EXPERT OPINION ON DRUG DELIVERY, 2020, 17 (04) : 573 - 587
  • [37] Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC
    Piao, Junjie
    Chen, Liyan
    Quan, Taihao
    Li, Longshan
    Quan, Chunji
    Piao, Yingshi
    Jin, Tiefeng
    Lin, Zhenhua
    ONCOTARGET, 2016, 7 (37) : 60169 - 60180
  • [38] Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway
    Chen, Dongshao
    Lin, Xiaoting
    Zhang, Cheng
    Liu, Zhentao
    Chen, Zuhua
    Li, Zhongwu
    Wang, Jingyuan
    Li, Beifang
    Hu, Yanting
    Dong, Bin
    Shen, Lin
    Ji, Jiafu
    Gao, Jing
    Zhang, Xiaotian
    CELL DEATH & DISEASE, 2018, 9
  • [39] The effect combining the KIT inhibitor Imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal tumor cell lines
    Li, Fang
    Growney, Joseph
    Battalagine, Linda
    Qiu, Shumei
    Manley, Paul
    Monahan, John
    CANCER RESEARCH, 2012, 72
  • [40] Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors
    Starks, David C.
    Rojas-Espaillat, Luis
    Meissner, Tobias
    Williams, Casey B.
    GYNECOLOGIC ONCOLOGY, 2022, 166 (03) : 403 - 409
12345